Interstitial prostatism model animal

• US 7,417,175 B2
• Filed: 05/08/2002
• Issued: 08/26/2008
• Est. Priority Date: 05/09/2001
• Status: Expired due to Fees

• Current Assignee: Taiho Pharmaceutical Company Limited (Otsuka Holdings Company Limited)
• Original Assignee: Taiho Pharmaceutical Company Limited (Otsuka Holdings Company Limited)
• Inventors: Miyake, Hidekazu, Oda, Nobuyuki, Miyoshi, Kazuhisa, Haruno, Akihiro
• Primary Examiner(s): Paras, Jr.; Peter
• Assistant Examiner(s): Montanari; David A.
• Application Number:
  US10/477,077
• Publication Number:
  US 20040139486A1
• Time in Patent Office: 2,302 Days
• Field of Search: 800/3, 800/8, 800/21, 800/18
• US Class Current: 800/18
• CPC Class Codes: A01K 2227/105 Murine
• CPC Class Codes: A01K 2267/0331 Animal model for proliferative diseases
• CPC Class Codes: A01K 67/0271 Chimeric vertebrates, e.g. comprising exogenous cells
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 5/0683 Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells spermatogonia C12N5/061
• CPC Class Codes: G01N 2800/342 Prostate diseases, e.g. BPH, prostatitis
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

The present invention provides an animal model for prostatic stromal hyperplasia, and a method for screening for a substance effective for preventing/treating human benign prostatic hyperplasia using the animal model. The animal model for prostatic stromal hyperplasia is produced by implanting the fetal urogenital sinus of a non-human animal under the skin or beneath the prostatic capsule of a non-human animal belonging to the species of the same as or different from the animal. A substance effective for preventing/treating human benign prostatic hyperplasia can be screened by administering a test substance to the animal model and measuring the preventive or therapeutic effect of the test substance upon the implanted tissue (fetal urogenital sinus or tissue derived therefrom).

Claims

1. A mouse or rat model for prostatic stromal hyperplasia comprising a rat or mouse having an implanted fetal urogenital sinus from a donor mouse or rat implanted directly beneath the prostatic capsule, but not within the prostate gland, wherein said rat or mouse is genetically immunodeficient or is syngeneic to the mouse or rat from which the extraneous fetal urogenital sinus was obtained and wherein said mouse or rat exhibits prostatic stromal hyperplasia.

3. A method of screening a test substance for the treatment of benign prostatic stromal hyperplasia comprising:

(i) administering a test substance to the rat or mouse model of prostatic stromal hyperplasia of claim 1; and

(ii) measuring a change in the stromal area ratio or weight of the implanted extraneous urogenital sinus in comparison to a control rat or mouse model of prostatic stromal hyperplasia which was not administered said test substance, wherein a reduction in said stromal area ratio or weight of the implanted extraneous urogenital sinus when compared to said control rat or mouse model indicates that said test substance is a treatment for benign prostatic stromal hyperplasia.

2. A method for producing a rat or mouse model for prostatic stromal hyperplasia comprising:

implanting a fetal urogenital sinus of a male mouse or rat beneath the prostatic capsule of a mouse or rat that is syngeneic to the mouse or rat from which the urogenital sinus was obtained or beneath the prostatic capsule of genetically immunodeficient mouse or rat, wherein said implantation results in stroma-enlarged tissues under the prostatic capsule in said mouse or rat.